Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Stock Has Consensus Price Target of $8.20

Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) have received an average recommendation of “Reduce” from the twelve brokerages that are currently covering the firm, Marketbeat.com reports. Four equities research analysts have rated the stock with a sell recommendation, seven have issued a hold recommendation and one has given a buy recommendation to the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $8.20.

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Fulcrum Therapeutics in a report on Thursday, October 15th.

Hedge Funds Weigh In On Fulcrum Therapeutics

A number of institutional investors have recently modified their holdings of FULC. Nisa Investment Advisors LLC grew its holdings in Fulcrum Therapeutics by 538.3% during the third quarter. Nisa Investment Advisors LLC now owns 20,177 shares of the company’s stock worth $75,000 after acquiring an additional 17,016 shares during the period. Engineers Gate Manager LP raised its position in Fulcrum Therapeutics by 91.9% during the second quarter. Engineers Gate Manager LP now owns 242,000 shares of the company’s stock valued at $886,000 after acquiring an additional 115,891 shares in the last quarter. AXQ Capital LP raised its position in Fulcrum Therapeutics by 269.7% during the second quarter. AXQ Capital LP now owns 81,483 shares of the company’s stock valued at $298,000 after acquiring an additional 59,440 shares in the last quarter. Headlands Technologies LLC acquired a new position in Fulcrum Therapeutics in the second quarter valued at approximately $328,000. Finally, Hsbc Holdings PLC lifted its holdings in Fulcrum Therapeutics by 86.5% in the second quarter. Hsbc Holdings PLC now owns 109,353 shares of the company’s stock valued at $426,000 after acquiring an additional 50,717 shares during the period. Hedge funds and other institutional investors own 89.83% of the company’s stock.

Fulcrum Therapeutics Stock Performance

Shares of NASDAQ FULC opened at $3.68 on Wednesday. Fulcrum Therapeutics has a 12 month low of $2.83 and a 12 month high of $15.74. The company has a 50 day simple moving average of $3.78 and a two-hundred day simple moving average of $4.67.

Fulcrum Therapeutics (NASDAQ:FULC) last released its quarterly earnings data on Thursday, July 30th. The company reported ($0.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.10). Equities research analysts forecast that Fulcrum Therapeutics will post -0.60 earnings per share for the current year.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing medicines for genetically driven diseases. The company’s research approach is based on selectively modulating gene expression to address the underlying biology of disease rather than targeting individual symptoms.

Fulcrum’s lead investigational program is losmapimod, an oral small-molecule therapy being developed for facioscapulohumeral muscular dystrophy (FSHD), a rare and progressive genetic muscle disorder.